$10.77
6.21% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Arcutis Biotherapeutics Inc Stock price

$10.77
+2.02 23.09% 1M
+1.61 17.58% 6M
+7.54 233.44% YTD
+8.81 449.49% 1Y
-6.96 39.26% 3Y
-11.03 50.60% 5Y
-11.03 50.60% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.63 6.21%
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Key metrics

Market capitalization $1.26b
Enterprise Value $1.14b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.20
P/S ratio (TTM) P/S ratio 9.09
P/B ratio (TTM) P/B ratio 8.04
Revenue growth (TTM) Revenue growth 182.84%
Revenue (TTM) Revenue $138.71m
EBIT (operating result TTM) EBIT $-181.93m
Free Cash Flow (TTM) Free Cash Flow $-167.80m
Cash position $331.18m
EPS (TTM) EPS $-1.79
P/E forward negative
P/S forward 7.00
EV/Sales forward 6.31
Short interest 29.35%
Show more

Is Arcutis Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Arcutis Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Arcutis Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
139 139
3,659% 3,659%
100%
- Direct Costs 15 15
763% 763%
11%
124 124
6,133% 6,133%
89%
- Selling and Administrative Expenses 218 218
81% 81%
157%
- Research and Development Expense 86 86
53% 53%
62%
-179 -179
40% 40%
-129%
- Depreciation and Amortization 2.53 2.53
124% 124%
2%
EBIT (Operating Income) EBIT -182 -182
40% 40%
-131%
Net Profit -196 -196
37% 37%
-141%

In millions USD.

Don't miss a Thing! We will send you all news about Arcutis Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcutis Biotherapeutics Inc Stock News

Positive
Seeking Alpha
11 days ago
Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% quarter-over-quarter revenue growth. The growth trend seems poised to continue, with an expanding total patient opportunity and the industry trending away from topical steroids, which present lower e...
Neutral
Seeking Alpha
19 days ago
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan...
Neutral
GlobeNewsWire
20 days ago
Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15%; sales growth of 452% vs. Q3 '23 and 45% vs.
More Arcutis Biotherapeutics Inc News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.

Head office United States
CEO Todd Watanabe
Employees 296
Founded 2016
Website www.arcutis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today